S100A8 and S100A9: DAMPs at the crossroads between innate immunity, traditional risk factors, and cardiovascular disease

Mediators of Inflammation

Volumn 2013, Issue , 2013, Pages

  Schiopu, Alexandru ^a,b   Cotoi, Ovidiu S ^c  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; CALGRANULIN A; CALGRANULIN B; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR 4; VASCULAR CELL ADHESION MOLECULE 1; QUINOLINE 3 CARBOXAMIDE; QUINOLINE DERIVATIVE; QUINOLINE-3-CARBOXAMIDE;

ACUTE CORONARY SYNDROME; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CYTOKINE PRODUCTION; DIABETES MELLITUS; DISEASE COURSE; DYSLIPIDEMIA; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE NECROSIS; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; INNATE IMMUNITY; MONOCYTE; NEUTROPHIL; NEUTROPHIL COUNT; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; REPERFUSION INJURY; SMOKING; SYSTEMIC LUPUS ERYTHEMATOSUS; ANIMAL; BLOOD; PHYSIOLOGY; REVIEW; RISK FACTOR;

ACUTE CORONARY SYNDROME; ANIMALS; ATHEROSCLEROSIS; CALGRANULIN A; CALGRANULIN B; CARDIOVASCULAR DISEASES; HUMANS; IMMUNITY, INNATE; QUINOLINES; RISK FACTORS;

EID: 84896360122     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2013/828354     Document Type: Article

References (107)

1. Weber C., Noels H., Atherosclerosis: current pathogenesis and therapeutic options. Nature Medicine 2011 17 11 1410 1422 2-s2.0-81255188900 10.1038/nm.2538
2. Hansson G. K., Hermansson A., The immune system in atherosclerosis. Nature Immunology 2011 12 3 204 212 2-s2.0-79951669207 10.1038/ni.2001
3. Newton K., Dixit V. M., Signaling in innate immunity and inflammation. Cold Spring Harbor Perspectives in Biology 2012 4 3
4. Chan J. K., Roth J., Oppenheim J. J., Alarmins: awaiting a clinical response. The Journal of Clinical Investigation 2012 122 8 2711 2719
5. Foell D., Wittkowski H., Vogl T., Roth J., S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. Journal of Leukocyte Biology 2007 81 1 28 37 2-s2.0-33845868493 10.1189/jlb.0306170 (Pubitemid 46021248)
6. Wolf R., Howard O. M. Z., Dong H.-F., Voscopoulos C., Boeshans K., Winston J., Divi R., Gunsior M., Goldsmith P., Ahvazi B., Chavakis T., Oppenheim J. J., Yuspa S. H., Chemotactic activity of S100A7 (psoriasin) is mediated by the receptor for advanced glycation end products and potentiates inflammation with highly homologous but functionally distinct S100A15. Journal of Immunology 2008 181 2 1499 1506 2-s2.0-49049094277
7. Foell D., Wittkowski H., Roth J., Mechanisms of Disease: a "DAMP" view of inflammatory arthritis. Nature Clinical Practice Rheumatology 2007 3 7 382 390 2-s2.0-34447131097 10.1038/ncprheum0531 (Pubitemid 47034539)
8. Edgeworth J., Gorman M., Bennett R., Freemont P., Hogg N., Identification of p8,14 as a highly abundant heterodimeric calcium binding protein complex of myeloid cells. Journal of Biological Chemistry 1991 266 12 7706 7713 2-s2.0-0025900907 (Pubitemid 21906422)
9. Averill M. M., Kerkhoff C., Bornfeldt K. E., S100A8 and S100A9 in cardiovascular biology and disease. Arteriosclerosis, Thrombosis, and Vascular Biology 2012 32 2 223 229 2-s2.0-84856221728 10.1161/ATVBAHA.111.236927
10. Goyette J., Yan W. X., Yamen E., Chung Y. M., Lim S. Y., Hsu K., Rahimi F., Di Girolamo N., Song C., Jessup W., Kockx M., Bobryshev Y. V., Freedman S. B., Geczy C. L., Pleiotropic roles of S100A12 in coronary atherosclerotic plaque formation and rupture. Journal of Immunology 2009 183 1 593 603 2-s2.0-68949085246 10.4049/jimmunol.0900373
11. Zhao P., Wu M., Yu H., Serum S100A12 levels are correlated with the presence and severity of coronary artery disease in patients with type 2 diabetes mellitus. Journal of Investigative Medicine 2013 61 5 861 866
12. Abbas A., Aukrust P., Dahl T. B., Bjerkeli V., Sagen E. B. L., Michelsen A., Russell D., Sørensen K. K., Holm S., Skjelland M., Halvorsen B., High levels of S100A12 are associated with recent plaque symptomatology in patients with carotid atherosclerosis. Stroke 2012 43 5 1347 1353 2-s2.0-84860221352 10.1161/STROKEAHA.111.642256
13. Averill M. M., Barnhart S., Becker L., Li X., Heinecke J. W., Leboeuf R. C., Hamerman J. A., Sorg C., Kerkhoff C., Bornfeldt K. E., S100A9 differentially modifies phenotypic states of neutrophils, macrophages, and dendritic cells: implications for atherosclerosis and adipose tissue inflammation. Circulation 2011 123 11 1216 1226 2-s2.0-79953052839 10.1161/CIRCULATIONAHA.110.985523
14. Xu K., Geczy C. L., IFN- γ and TNF regulate macrophage expression of the chemotactic S100 protein S100A8. Journal of Immunology 2000 164 9 4916 4923 2-s2.0-0034194261 (Pubitemid 30238097)
15. Xu K., Yen T., Geczy C. L., IL-10 up-regulates macrophage expression of the S100 protein S100A8. Journal of Immunology 2001 166 10 6358 6366 2-s2.0-0035873775 (Pubitemid 32440769)
16. Hu S.-P., Harrison C., Xu K., Cornish C. J., Geczy C. L., Induction of the chemotactic S100 protein, CP-10, in monocyte/macrophages by lipopolysaccharide. Blood 1996 87 9 3919 3928 2-s2.0-0029962212 (Pubitemid 26130614)
17. Yao D., Brownlee M., Hyperglycemia-induced reactive oxygen species increase expression of the receptor for advanced glycation end products (RAGE) and RAGE ligands. Diabetes 2010 59 1 249 255 2-s2.0-77449142258 10.2337/db09-0801
18. McCormick M. M., Rahimi F., Bobryshev Y. V., Gaus K., Zreiqat H., Cai H., Lord R. S. A., Geczy C. L., S100A8 and S100A9 in human arterial wall: implications for atherogenesis. Journal of Biological Chemistry 2005 280 50 41521 41529 2-s2.0-29244446785 10.1074/jbc.M509442200 (Pubitemid 41832213)
19. Yen T., Harrison C. A., Devery J. M., Leong S., Iismaa S. E., Yoshimura T., Geczy C. L., Induction of the S100 chemotactic protein, CP-10, in murine microvascular endothelial cells by proinflammatory stimuli. Blood 1997 90 12 4812 4821 2-s2.0-0031452336 (Pubitemid 28007195)
20. Rahimi F., Hsu K., Endoh Y., Geczy C. L., FGF-2, IL-1 β and TGF- β regulate fibroblast expression of S100A8. FEBS Journal 2005 272 11 2811 2827 2-s2.0-20444501382 10.1111/j.1742-4658.2005.04703.x (Pubitemid 40825427)
21. Grimbaldeston M. A., Geczy C. L., Tedla N., Finlay-Jones J. J., Hart P. H., S100A8 induction in keratinocytes by ultraviolet a irradiation is dependent on reactive oxygen intermediates. Journal of Investigative Dermatology 2003 121 5 1168 1174 2-s2.0-0242490068 10.1046/j.1523-1747.2003.12561.x (Pubitemid 37430989)
22. Ingersoll M. A., Spanbroek R., Lottaz C., Comparison of gene expression profiles between human and mouse monocyte subsets. Blood 2010 115 3 e10 e19
23. Vogl T., Ludwig S., Goebeler M., Strey A., Thorey I. S., Reichelt R., Foell D., Gerke V., Manitz M. P., Nacken W., Werner S., Sorg C., Roth J., MRP8 and MRP14 control microtubule reorganization during transendothelial migration of phagocytes. Blood 2004 104 13 4260 4268 2-s2.0-10244235212 10.1182/blood-2004-02-0446 (Pubitemid 39620181)
24. Nacken W., Roth J., Sorg C., Kerkhoff C., S100A9/S100A8: myeloid representatives of the S100 protein family as prominent players in innate immunity. Microscopy Research and Technique 2003 60 6 569 580 2-s2.0-0242335600
25. Ehrchen J. M., Sunderkötter C., Foell D., Vogl T., Roth J., The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. Journal of Leukocyte Biology 2009 86 3 557 566 2-s2.0-67649208478 10.1189/jlb.1008647
26. Cotoi O. S., Duner P., Ko N., Plasma S100A8/A9 correlates with blood neutrophil counts, traditional risk factors, and cardiovascular disease in middle-aged healthy individuals. Arteriosclerosis, Thrombosis, and Vascular Biology 2013 10.1161/ATVBAHA.113.302432
27. Goyette J., Geczy C. L., Inflammation-associated S100 proteins: new mechanisms that regulate function. Amino Acids 2011 41 4 821 842 2-s2.0-81555205312 10.1007/s00726-010-0528-0
28. Viemann D., Strey A., Janning A., Jurk K., Klimmek K., Vogl T., Hirono K., Ichida F., Foell D., Kehrel B., Gerke V., Sorg C., Roth J., Myeloid-related proteins 8 and 14 induce a specific inflammatory response in human microvascular endothelial cells. Blood 2005 105 7 2955 2962 2-s2.0-19944417730 10.1182/blood-2004-07-2520 (Pubitemid 40446292)
29. Bouma G., Lam-Tse W. K., Wierenga-Wolf A. F., Drexhage H. A., Versnel M. A., Increased serum levels of MRP-8/14 in type 1 diabetes induce an increased expression of CD11b and an enhanced adhesion of circulating monocytes to fibronectin. Diabetes 2004 53 8 1979 1986 2-s2.0-3242811249 10.2337/diabetes.53. 8.1979 (Pubitemid 38970745)
30. Eue I., Pietz B., Storck J., Klempt M., Sorg C., Transendothelial migration of 27E10+ human monocytes. International Immunology 2000 12 11 1593 1604 2-s2.0-0033730549
31. Newton R. A., Hogg N., The human S100 protein MRP-14 is a novel activator of the β 2 integrin Mac-1 on neutrophils. Journal of Immunology 1998 160 3 1427 1435 2-s2.0-0031892521 (Pubitemid 28093444)
32. Ryckman C., Vandal K., Rouleau P., Talbot M., Tessier P. A., Proinflammatory activities of S100: proteins S100A8, S100A9, and S100A8/A9 induce neutrophil chemotaxis and adhesion. Journal of Immunology 2003 170 6 3233 3242 2-s2.0-0037443667 (Pubitemid 36302201)
33. Sroussi H. Y., Berline J., Dazin P., Green P., Palefsky J. M., S100A8 triggers oxidation-sensitive repulsion of neutrophils. Journal of Dental Research 2006 85 9 829 833 2-s2.0-33748783040 (Pubitemid 44409033)
34. Sroussi H. Y., Berline J., Palefsky J. M., Oxidation of methionine 63 and 83 regulates the effect of S100A9 on the migration of neutrophils in vitro. Journal of Leukocyte Biology 2007 81 3 818 824 2-s2.0-33847773908 10.1189/jlb.0706433 (Pubitemid 46393560)
35. Gomes L. H., Raftery M. J., Yan W. X., Goyette J. D., Thomas P. S., Geczy C. L., S100A8 and S100A9-oxidant scavengers in inflammation. Free Radical Biology & Medicine 2013 58 170 186
36. Isaksen B., Fagerhol M. K., Calprotectin inhibits matrix metalloproteinases by sequestration of zinc. Journal of Clinical Pathology 2001 54 5 289 292 2-s2.0-0034803028 10.1136/mp.54.5.289 (Pubitemid 32928253)
37. De Lorenzo B. H. P., Godoy L. C., Novaes e Brito R. R., Pagano R. L., Amorim-Dias M. A., Grosso D. M., Lopes J. D., Mariano M., Macrophage suppression following phagocytosis of apoptotic neutrophils is mediated by the S100A9 calcium-binding protein. Immunobiology 2010 215 5 341 347 2-s2.0-77950951777 10.1016/j.imbio.2009.05.013
38. Sroussi H. Y., Lu Y., Zhang Q. L., Villines D., Marucha P. T., S100A8 and S100A9 inhibit neutrophil oxidative metabolism in-vitro: involvement of adenosine metabolites. Free Radical Research 2010 44 4 389 396 2-s2.0-77949385445 10.3109/10715760903431434
39. Sroussi H. Y., Lu Y., Villines D., Sun Y., The down regulation of neutrophil oxidative metabolism by S100A8 and S100A9: implication of the protease-activated receptor-2. Molecular Immunology 2012 50 1-2 42 48 2-s2.0-84857063394 10.1016/j.molimm.2011.12.001
40. Vogl T., Tenbrock K., Ludwig S., Leukert N., Ehrhardt C., Van Zoelen M. A. D., Nacken W., Foell D., Van Der Poll T., Sorg C., Roth J., Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nature Medicine 2007 13 9 1042 1049 2-s2.0-34948900275 10.1038/nm1638 (Pubitemid 47517513)
41. Harja E., Bu D.-X., Hudson B. I., Jong S. C., Shen X., Hallam K., Kalea A. Z., Lu Y., Rosario R. H., Oruganti S., Nikolla Z., Belov D., Lalla E., Ramasamy R., Shi F. Y., Schmidt A. M., Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/- mice. Journal of Clinical Investigation 2008 118 1 183 194 2-s2.0-38149078193 10.1172/JCI32703
42. Björk P., Björk A., Vogl T., Stenström M., Liberg D., Olsson A., Roth J., Ivars F., Leanderson T., Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides. PLoS Biology 2009 7 4 e97 2-s2.0-67649413681 10.1371/journal.pbio.1000097
43. + T cells. Nature Medicine 2010 16 6 713 717 2-s2.0-77953233075 10.1038/nm.2150
44. Riva M., Kallberg E., Bjork P., Induction of nuclear factor-kappaB responses by the S100A9 protein is Toll-like receptor-4-dependent. Immunology 2012 137 2 172 182
45. Holzinger D., Frosch M., Kastrup A., Prince F. H. M., Otten M. H., Van Suijlekom-Smit L. W. A., Ten Cate R., Hoppenreijs E. P. A. H., Hansmann S., Moncrieffe H., Ursu S., Wedderburn L. R., Roth J., Foell D., Wittkowski H., The Toll-like receptor 4 agonist MRP8/14 protein complex is a sensitive indicator for disease activity and predicts relapses in systemic-onset juvenile idiopathic arthritis. Annals of the Rheumatic Diseases 2012 71 974 980 2-s2.0-84856012464 10.1136/annrheumdis-2011-200598
46. Lee D. G., Woo J. W., Kwok S. K., Cho M. L., Park S. H., MRP8 promotes Th17 differentiation via upregulation of IL-6 production by fibroblast-like synoviocytes in rheumatoid arthritis. Experimental & Molecular Medicine 2013 45, article e20
47. Källberg E., Vogl T., Liberg D., Olsson A., Björk P., Wikström P., Bergh A., Roth J., Ivars F., Leanderson T., S100a9 interaction with tlr4 promotes tumor growth. PLoS ONE 2012 7 3 2-s2.0-84859044056 10.1371/journal.pone.0034207 e34207
48. Yonekawa K., Neidhart M., Altwegg L. A., Wyss C. A., Corti R., Vogl T., Grigorian M., Gay S., Lüscher T. F., Maier W., Myeloid related proteins activate Toll-like receptor 4 in human acute coronary syndromes. Atherosclerosis 2011 218 2 486 492 2-s2.0-80053270737 10.1016/j.atherosclerosis.2011.06.020
49. Nagareddy P. R., Murphy A. J., Stirzaker R. A., Hyperglycemia promotes myelopoiesis and impairs the resolution of atherosclerosis. Cell Metabolism 2013 17 5 695 708
50. Turovskaya O., Foell D., Sinha P., Vogl T., Newlin R., Nayak J., Nguyen M., Olsson A., Nawroth P. P., Bierhaus A., Varki N., Kronenberg M., Freeze H. H., Srikrishna G., RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis. Carcinogenesis 2008 29 10 2035 2043 2-s2.0-53349173233 10.1093/carcin/bgn188
51. Gebhardt C., Riehl A., Durchdewald M., Németh J., Fürstenberger G., Müller-Decker K., Enk A., Arnold B., Bierhaus A., Nawroth P. P., Hess J., Angel P., RAGE signaling sustains inflammation and promotes tumor development. Journal of Experimental Medicine 2008 205 2 275 285 2-s2.0-39549098128 10.1084/jem.20070679 (Pubitemid 351281593)
52. Ghavami S., Rashedi I., Dattilo B. M., Eshraghi M., Chazin W. J., Hashemi M., Wesselborg S., Kerkhoff C., Los M., S100A8/A9 at low concentration promotes tumor cell growth via RAGE ligation and MAP kinase-dependent pathway. Journal of Leukocyte Biology 2008 83 6 1484 1492 2-s2.0-38349052450 10.1189/jlb.0607397 (Pubitemid 351960330)
53. Boyd J. H., Kan B., Roberts H., Wang Y., Walley K. R., S100A8 and S100A9 mediate endotoxin-induced cardiomyocyte dysfunction via the receptor for advanced glycation end products. Circulation Research 2008 102 10 1239 1246 2-s2.0-45149098188 10.1161/CIRCRESAHA.107.167544
54. Volz H. C., Laohachewin D., Seidel C., Lasitschka F., Keilbach K., Wienbrandt A. R., Andrassy J., Bierhaus A., Kaya Z., Katus H. A., Andrassy M., S100A8/A9 aggravates post-ischemic heart failure through activation of RAGE-dependent NF- B signaling. Basic Research in Cardiology 2012 107 2, article 0250 2-s2.0-84856573048 10.1007/s00395-012-0250-z
55. Eggers K., Sikora K., Lorenz M., Taubert T., Moobed M., Baumann G., Stangl K., Stangl V., RAGE-dependent regulation of calcium-binding proteins S100A8 and S100A9 in human THP-1. Experimental and Clinical Endocrinology and Diabetes 2011 119 6 353 357 2-s2.0-79958273980 10.1055/s-0030-1268426
56. Ehlermann P., Eggers K., Bierhaus A., Most P., Weichenhan D., Greten J., Nawroth P. P., Katus H. A., Remppis A., Increased proinflammatory endothelial response to S100A8/A9 after preactivation through advanced glycation end products. Cardiovascular Diabetology 2006 5, article 6 2-s2.0-33745096005 10.1186/1475-2840-5-6 (Pubitemid 43880425)
57. Robinson M. J., Tessier P., Poulsom R., Hogg N., The S100 family heterodimer, MRP-8/14, binds with high affinity to heparin and heparan sulfate glycosaminoglycans on endothelial cells. Journal of Biological Chemistry 2002 277 5 3658 3665 2-s2.0-0036479102 10.1074/jbc.M102950200 (Pubitemid 34953239)
58. Srikrishna G., Panneerselvam K., Westphal V., Abraham V., Varki A., Freeze H. H., Two proteins modulating transendothelial migration of leukocytes recognize novel carboxylated glycans on endothelial cells. Journal of Immunology 2001 166 7 4678 4688 2-s2.0-0035313549 (Pubitemid 32233755)
59. Viemann D., Barczyk K., Vogl T., Fischer U., Sunderkötter C., Schulze-Osthoff K., Roth J., MRP8/MRP14 impairs endothelial integrity and induces a caspase-dependent and -independent cell death program. Blood 2007 109 6 2453 2460 2-s2.0-33947272221 10.1182/blood-2006-08-040444 (Pubitemid 46425888)
60. Stocca A., O'Toole D., Hynes N., Hynes S. O., Mashayekhi K., McGinley L., O'Connell E., Coleman C., Sultan S., Duffy A., Tunev S., O'Brien T., A Role for MRP8 in in stent restenosis in diabetes. Atherosclerosis 2012 221 2 325 332 2-s2.0-84858707584 10.1016/j.atherosclerosis.2012.01.036
61. Lim S. Y., Raftery M. J., Geczy C. L., Oxidative modifications of DAMPs suppress inflammation: the case for S100A8 and S100A9. Antioxidants and Redox Signaling 2011 15 8 2235 2248 2-s2.0-80052560779 10.1089/ars.2010.3641
62. Sroussi H. Y., Köhler G. A., Agabian N., Villines D., Palefsky J. M., Substitution of methionine 63 or 83 in S100A9 and cysteine 42 in S100A8 abrogate the antifungal activities of S100A8/A9: potential role for oxidative regulation. FEMS Immunology and Medical Microbiology 2009 55 1 55 61 2-s2.0-58149295902 10.1111/j.1574-695X.2008.00498.x
63. Ortega F. J., Sabater M., Moreno-Navarrete J. M., Serum and urinary concentrations of calprotectin as markers of insulin resistance and type 2 diabetes. European Journal of Endocrinology 2012 167 4 569 578
64. Mortensen O. H., Nielsen A. R., Erikstrup C., Plomgaard P., Fischer C. P., Krogh-Madsen R., Lindegaard B., Petersen A. M., Taudorf S., Philip C., Calprotectin-a novel marker of obesity. PLoS ONE 2009 4 10 2-s2.0-70350719452 10.1371/journal.pone.0007419 e7419
65. Sekimoto R., Kishida K., Nakatsuji H., Nakagawa T., Funahashi T., Shimomura I., High circulating levels of S100A8/A9 complex (calprotectin) in male Japanese with abdominal adiposity and dysregulated expression of S100A8 and S100A9 in adipose tissues of obese mice. Biochemical and Biophysical Research Communications 2012 419 4 782 789 2-s2.0-84858752110 10.1016/j.bbrc.2012.02.102
66. Smith M. R., Kinmonth A.-L., Luben R. N., Bingham S., Day N. E., Wareham N. J., Welch A., Khaw K.-T., Smoking status and differential white cell count in men and women in the EPIC-Norfolk population. Atherosclerosis 2003 169 2 331 337 2-s2.0-0142029099 10.1016/S0021-9150(03)00200-4 (Pubitemid 37297481)
67. Drechsler M., Megens R. T. A., Van Zandvoort M., Weber C., Soehnlein O., Hyperlipidemia-triggered neutrophilia promotes early atherosclerosis. Circulation 2010 122 18 1837 1845 2-s2.0-78349304885 10.1161/CIRCULATIONAHA.110. 961714
68. Soehnlein O., Multiple roles for neutrophils in atherosclerosis. Circulation Research 2012 110 6 875 888 2-s2.0-84858630089 10.1161/CIRCRESAHA. 111.257535
69. Zernecke A., Bot I., Djalali-Talab Y., Shagdarsuren E., Bidzhekov K., Meiler S., Krohn R., Schober A., Sperandio M., Soehnlein O., Bornemann J., Tacke F., Biessen E. A., Weber C., Protective role of CXC receptor 4/CXC ligand 12 unveils the importance of neutrophils in atherosclerosis. Circulation Research 2008 102 2 209 217 2-s2.0-41149085145 10.1161/CIRCRESAHA.107.160697 (Pubitemid 351651125)
70. de Jager S. C., Bot I., Kraaijeveld A. O., Leukocyte-specific CCL3 deficiency inhibits atherosclerotic lesion development by affecting neutrophil accumulation. Arteriosclerosis, Thrombosis, and Vascular Biology 2013 33 3 e75 e83
71. Maiseyeu A., Badgeley M. A., Kampfrath T., Mihai G., Deiuliis J. A., Liu C., Sun Q., Parthasarathy S., Simon D. I., Croce K., Rajagopalan S., In vivo targeting of inflammation-associated myeloid-related protein 8/14 via gadolinium immunonanoparticles. Arteriosclerosis, Thrombosis, and Vascular Biology 2012 32 4 962 970 2-s2.0-84858709249 10.1161/ATVBAHA.111.244509
72. Ionita M. G., Vink A., Dijke I. E., Laman J. D., Peeters W., Van Der Kraak P. H., Moll F. L., De Vries J.-P. P. M., Pasterkamp G., De Kleijn D. P. V., High levels of myeloid-related protein 14 in human atherosclerotic plaques correlate with the characteristics of rupture-prone lesions. Arteriosclerosis, Thrombosis, and Vascular Biology 2009 29 8 1220 1227 2-s2.0-68149159961 10.1161/ATVBAHA.109.190314
73. Eue I., Langer C., Eckardstein A. V., Sorg C., Myeloid related protein (MRP) 14 expressing monocytes acpnRPom RPP. Atherosclerosis 2000 151 2 593 597 2-s2.0-0033861097 10.1016/S0021-9150(00)00476-7 (Pubitemid 30618781)
74. Michelsen K. S., Wong M. H., Shah P. K., Zhang W., Yano J., Doherty T. M., Akira S., Rajavashisth T. B., Arditi M., Lack of toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proceedings of the National Academy of Sciences of the United States of America 2004 101 29 10679 10684 2-s2.0-3242710174 10.1073/pnas.0403249101 (Pubitemid 38955802)
75. Björkbacka H., Kunjathoor V. V., Moore K. J., Koehn S., Ordija C. M., Lee M. A., Means T., Halmen K., Luster A. D., Golenbock D. T., Freeman M. W., Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nature Medicine 2004 10 4 416 421 2-s2.0-3242728901 10.1038/nm1008 (Pubitemid 38508522)
76. Cipollone F., Iezzi A., Fazia M., Zucchelli M., Pini B., Cuccurullo C., De Cesare D., De Blasis G., Muraro R., Bei R., Chiarelli F., Schmidt A. M., Cuccurullo F., Mezzetti A., The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Circulation 2003 108 9 1070 1077 2-s2.0-0041315638 10.1161/01.CIR.0000086014.80477.0D (Pubitemid 37071516)
77. Soro-Paavonen A., Watson A. M. D., Li J., Paavonen K., Koitka A., Calkin A. C., Barit D., Coughlan M. T., Drew B. G., Lancaster G. I., Thomas M., Forbes J. M., Nawroth P. P., Bierhaus A., Cooper M. E., Jandeleit-Dahm K. A., Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes 2008 57 9 2461 2469 2-s2.0-52749084063 10.2337/db07-1808
78. Hobbs J. A. R., May R., Tanousis K., McNeill E., Mathies M., Gebhardt C., Henderson R., Robinson M. J., Hogg N., Myeloid cell function in MRP-14 (S100A9) null mice. Molecular and Cellular Biology 2003 23 7 2564 2576 2-s2.0-0037377737 10.1128/MCB.23.7.2564-2576.2003 (Pubitemid 36351035)
79. Passey R. J., Williams E., Lichanska A. M., Wells C., Hu S., Geczy C. L., Little M. H., Hume D. A., A null mutation in the inflammation-associated S100 protein S100A8 causes early resorption of the mouse embryo. Journal of Immunology 1999 163 4 2209 2216 2-s2.0-0033566735 (Pubitemid 29382229)
80. Manitz M.-P., Horst B., Seeliger S., Strey A., Skryabin B. V., Gunzer M., Frings W., Schönlau F., Roth J., Sorg C., Nacken W., Loss of S100A9 (MRP14) results in reduced interleukin-8-induced CD11b surface expression, a polarized microfilament system, and diminished responsiveness to chemoattractants in vitro. Molecular and Cellular Biology 2003 23 3 1034 1043 2-s2.0-0037305848 10.1128/MCB.23.3.1034-1043.2003 (Pubitemid 36133519)
81. Schnekenburger J., Schick V., Krüger B., Manitz M. P., Sorg C., Nacken W., Kerkhoff C., Kahlert A., Mayerle J., Domschke W., Lerch M. M., The calcium binding protein S100A9 is essential for pancreatic leukocyte infiltration and induces disruption of cell-cell contacts. Journal of Cellular Physiology 2008 216 2 558 567 2-s2.0-46049086581 10.1002/jcp.21433 (Pubitemid 351898485)
82. Croce K., Gao H., Wang Y., Mooroka T., Sakuma M., Shi C., Sukhova G. K., Packard R. R. S., Hogg N., Libby P., Simon D. I., Myeloid-related protein-8/14 is critical for the biological response to vascular injury. Circulation 2009 120 5 427 436 2-s2.0-68249122142 10.1161/CIRCULATIONAHA.108.814582
83. Peng W. H., Jian W. X., Li H. L., Hou L., Wei Y. D., Li W. M., Xu Y. W., Increased serum myeloid-related protein 8/14 level is associated with atherosclerosis in type 2 diabetic patients. Cardiovascular Diabetology 2011 10, article 41 2-s2.0-79955966412 10.1186/1475-2840-10-41
84. Peng W. H., Jian W. X., Li H. L., Hou L., Wei Y. D., Li W. M., Xu Y. W., Increased serum myeloid-related protein 8/14 level is associated with atherosclerosis in type 2 diabetic patients. Cardiovascular Diabetology 2011 10, article 41 2-s2.0-79955966412 10.1186/1475-2840-10-41
85. Hirata A., Kishida K., Nakatsuji H., Hiuge-Shimizu A., Funahashi T., Shimomura I., High serum S100A8/A9 levels and high cardiovascular complication rate in type 2 diabetics with ultrasonographic low carotid plaque density. Diabetes Research and Clinical Practice 2012 97 1 82 90 2-s2.0-84856802808 10.1016/j.diabres.2012.01.026
86. Ionita M. G., Catanzariti L. M., Bots M. L., De Vries J.-P. P. M., Moll F. L., Sze Kwan S., Pasterkamp G., De Kleijn D. P. V., High myeloid-related protein: 8/14 levels are related to an increased risk of cardiovascular events after carotid endarterectomy. Stroke 2010 41 9 2010 2015 2-s2.0-77956411621 10.1161/STROKEAHA.110.582122
87. Healy A. M., Pickard M. D., Pradhan A. D., Wang Y., Chen Z., Croce K., Sakuma M., Shi C., Zago A. C., Garasic J., Damokosh A. I., Dowie T. L., Poisson L., Lillie J., Libby P., Ridker P. M., Simon D. I., Platelet expression profiling and clinical validation of myeloid-related protein-14 as a novel determinant of cardiovascular events. Circulation 2006 113 19 2278 2284 2-s2.0-33744997382 10.1161/CIRCULATIONAHA.105.607333 (Pubitemid 43947973)
88. Björnådal L., Yin L., Granath F., Klareskog L., Ekbom A., Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population based study 1964-95. Journal of Rheumatology 2004 31 4 713 719 2-s2.0-1842530440 (Pubitemid 38451257)
89. Tyden H., Lood C., Gullstrand B., Increased serum levels of S100A8/A9 and S100A12 are associated with cardiovascular disease in patients with inactive systemic lupus erythematosus. Rheumatology 2013 52 11 2048 2055 10.1093/rheumatology/ket263
90. Altwegg L. A., Neidhart M., Hersberger M., Müller S., Eberli F. R., Corti R., Roffi M., Sütsch G., Gay S., Von Eckardstein A., Wischnewsky M. B., Lüscher T. F., Maier W., Myeloid-related protein 8/14 complex is released by monocytes and granulocytes at the site of coronary occlusion: a novel, early, and sensitive marker of acute coronary syndromes. European Heart Journal 2007 28 8 941 948 2-s2.0-34548316925 10.1093/eurheartj/ehm078 (Pubitemid 47343918)
91. Du C.-Q., Yang L., Han J., Yang J., Yao X.-Y., Hu X.-S., Hu S.-J., The elevated serum S100A8/A9 during acute myocardial infarction is not of cardiac myocyte origin. Inflammation 2011 35 3 787 796 2-s2.0-80052148586 10.1007/s10753-011-9375-8
92. Katashima T., Naruko T., Terasaki F., Fujita M., Otsuka K., Murakami S., Sato A., Hiroe M., Ikura Y., Ueda M., Ikemoto M., Kitaura Y., Enhanced expression of the S100A8/A9 complex in acute myocardial infarction patients. Circulation Journal 2010 74 4 741 748 2-s2.0-77950637519 10.1253/circj.CJ-09- 0564
93. Vora A. N., Bonaca M. P., Ruff C. T., Jarolim P., Murphy S., Croce K., Sabatine M. S., Simon D. I., Morrow D. A., Diagnostic evaluation of the MRP-8/14 for the emergency assessment of chest pain. Journal of Thrombosis and Thrombolysis 2012 34 2 229 234 2-s2.0-84858731403 10.1007/s11239-012-0705-y
94. Krishnan U., Goodall A. H., Bugert P., Letter by Krishnan et al regarding article, 'platelet expression profiling and clinical validation of myeloid-related protein-14 as a novel determinant of cardiovascular events'. Circulation 2007 115 6, article e186 2-s2.0-33847092978 10.1161/CIRCULATIONAHA. 106.644419 (Pubitemid 46294753)
95. Satoh M., Shimoda Y., Maesawa C., Akatsu T., Ishikawa Y., Minami Y., Hiramori K., Nakamura M., Activated toll-like receptor 4 in monocytes is associated with heart failure after acute myocardial infarction. International Journal of Cardiology 2006 109 2 226 234 2-s2.0-33646116570 10.1016/j.ijcard. 2005.06.023
96. Zhao P., Wang J., He L., Ma H., Zhang X., Zhu X., Dolence E. K., Ren J., Li J., Deficiency in TLR4 signal transduction ameliorates cardiac injury and cardiomyocyte contractile dysfunction during ischemia. Journal of Cellular and Molecular Medicine 2009 13 8 1513 1525 2-s2.0-70349305528 10.1111/j.1582-4934. 2009.00798.x
97. Morrow D. A., Wang Y., Croce K., Sakuma M., Sabatine M. S., Gao H., Pradhan A. D., Healy A. M., Buros J., McCabe C. H., Libby P., Cannon C. P., Braunwald E., Simon D. I., Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Theraphy: thrombolysis in Myocardial Infarction (PROVE IT-TIMI 22) trial. American Heart Journal 2008 155 1 49 55 2-s2.0-36849078292 10.1016/j.ahj.2007.08.018 (Pubitemid 350234770)
98. Ma L.-P., Haugen E., Ikemoto M., Fujita M., Terasaki F., Fu M., S100A8/A9 complex as a new biomarker in prediction of mortality in elderly patients with severe heart failure. International Journal of Cardiology 2012 155 1 26 32 2-s2.0-84860015405 10.1016/j.ijcard.2011.01.082
99. Bengtsson A. A., Sturfelt G., Lood C., Rönnblom L., Van Vollenhoven R. F., Axelsson B., Sparre B., Tuvesson H., Öhman M. W., Leanderson T., Pharmacokinetics, tolerability, and preliminary efficacy of paquinimod (ABR-215757), a new quinoline-3-carboxamide derivative: studies in lupus-prone mice and a multicenter, randomized, double-blind, placebo-controlled, repeat-dose, dose-ranging study in patients with systemic lupus erythematosus. Arthritis and Rheumatism 2012 64 5 1579 1588 2-s2.0-84860460054 10.1002/art.33493
100. Karussis D. M., Lehmann D., Slavin S., Vourka-Karussis U., Mizrachi-Koll R., Ovadia H., Kalland T., Abramsky O., Treatment of chronic-relapsing experimental autoimmune encephalomyelitis with the synthetic immunomodulator linomide (quinoline-3-carboxamide). Proceedings of the National Academy of Sciences of the United States of America 1993 90 14 6400 6404 2-s2.0-0027197490 (Pubitemid 23207220)
101. Brunmark C., Runström A., Ohlsson L., Sparre B., Brodin T., Åström M., Hedlund G., The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis. Journal of Neuroimmunology 2002 130 1-2 163 172 2-s2.0-0036710356 10.1016/S0165-5728(02)00225-4 (Pubitemid 35240003)
102. Bjork J., Kleinau S., Paradoxical effects of LS-2616 (Linomide) treatment in the type II collagen arthritis model in mice. Agents and Actions 1989 27 3-4 319 321 2-s2.0-0024375029 (Pubitemid 19188631)
103. Polman C., Barkhof F., Sandberg-Wollheim M., Linde A., Nordle O., Nederman T., Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology 2005 64 6 987 991 2-s2.0-15244353263 (Pubitemid 40388448)
104. Coutant R., Landais P., Rosilio M., Johnsen C., Lahlou N., Chatelain P., Carel J. C., Ludvigsson J., Boitard C., Bougnères P. F., Low dose linomide in type I juvenile diabetes of recent onset: a randomised placebo-controlled double blind trial. Diabetologia 1998 41 9 1040 1046 2-s2.0-15444353015 10.1007/s001250051028 (Pubitemid 28394409)
105. Pili R., Haggman M., Stadler W. M., Gingrich J. R., Assikis V. J., Bjork A., Nordle O., Forsberg G., Carducci M. A., Armstrong A. J., Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. Journal of Clinical Oncology 2011 29 30 4022 4028 2-s2.0-80054761310 10.1200/JCO.2011.35. 6295
106. Yan L., Bjork P., Butuc R., Beneficial effects of quinoline-3-carboxamide (ABR-215757) on atherosclerotic plaque morphology in S100A12 transgenic ApoE null mice. Atherosclerosis 2013 228 1 69 79
107. Goldblatt F., O'Neill S. G., Clinical aspects of autoimmune rheumatic diseases. The Lancet 2013 382 9894 797 808